INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Dyne Therapeutics, Inc. - DYN

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- NEW YORK, June 30, 2025 (GLOBENEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the“Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at ... or 646-581-9980, ext. 7980.

The investigation concerns whether Dyne and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 17, 2025, Dyne Therapeutics issued a press release indicating a delay in filing for U.S. Food and Drug Administration (“FDA”) approval of DYNE-101, an experimental therapy for myotonic dystrophy type 1 (“DM1”). Following a Type C meeting with the FDA's Center for Drug Evaluation and Research in May, the Company agreed to a revised protocol for its Phase 1/2 global ACHIEVE trial for DYNE-101 in DM1, then submitted the revised protocol to the FDA in June, incorporating changes to ACHIEVE's ongoing Registrational Expansion Cohort. Dyne had previously set a goal to complete enrollments in the cohort in mid-2025 before generating data and submitting the regulatory submission in the first half of 2026. Under its revised schedule, however, Dyne intends to complete enrollment in the cohort in the fourth quarter of 2025, seeking a data readout in mid-2026 and a potential Accelerated Approval submission in late 2026.

On this news, Dyne's stock price fell $2.96 per share, or 21.42%, to close at $10.86 per share on June 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980

MENAFN06072025004107003653ID1109765626